Merck's top dealmaker signals more M&A as Keytruda's patent cliff nears

Summary

Merck CEO Robert Davis signals continued M&A activity to strengthen the pipeline as Keytruda approaches its patent cliff. The company has been pursuing deals with urgency to mitigate revenue risks from the blockbuster drug's exclusivity loss.